JP2020519663A - Rsv感染に対する防御免疫を誘導するための方法及び組成物 - Google Patents
Rsv感染に対する防御免疫を誘導するための方法及び組成物 Download PDFInfo
- Publication number
- JP2020519663A JP2020519663A JP2019563140A JP2019563140A JP2020519663A JP 2020519663 A JP2020519663 A JP 2020519663A JP 2019563140 A JP2019563140 A JP 2019563140A JP 2019563140 A JP2019563140 A JP 2019563140A JP 2020519663 A JP2020519663 A JP 2020519663A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- rsv
- protein
- adenovirus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000001939 inductive effect Effects 0.000 title claims abstract description 6
- 230000001681 protective effect Effects 0.000 title abstract description 14
- 230000036039 immunity Effects 0.000 title abstract description 7
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 title description 4
- 241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 116
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 104
- 239000013598 vector Substances 0.000 claims abstract description 94
- 150000007523 nucleic acids Chemical class 0.000 claims description 61
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 230000000890 antigenic effect Effects 0.000 claims description 42
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 230000028993 immune response Effects 0.000 claims description 18
- 229940001442 combination vaccine Drugs 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 abstract description 14
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 108090000565 Capsid Proteins Proteins 0.000 description 15
- 102100023321 Ceruloplasmin Human genes 0.000 description 15
- 241000598171 Human adenovirus sp. Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000004927 fusion Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 6
- 241001135569 Human adenovirus 5 Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000990167 unclassified Simian adenoviruses Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101710145505 Fiber protein Proteins 0.000 description 4
- 101710094396 Hexon protein Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101710173835 Penton protein Proteins 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 101100165660 Alternaria brassicicola bsc6 gene Proteins 0.000 description 2
- 101100499295 Bacillus subtilis (strain 168) disA gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150007210 ORF6 gene Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101100226894 Phomopsis amygdali PaGT gene Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000701106 Bovine adenovirus 3 Species 0.000 description 1
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 1
- 101710159767 C4b-binding protein alpha chain Proteins 0.000 description 1
- 241000701157 Canine mastadenovirus A Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124679 RSV vaccine Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 241001217859 Simian adenovirus 1 Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- NTGGOTYRTOXKMQ-UHFFFAOYSA-K aluminum;potassium;phosphate Chemical compound [Al+3].[K+].[O-]P([O-])([O-])=O NTGGOTYRTOXKMQ-UHFFFAOYSA-K 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- -1 pe Species 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 101150088856 pix gene Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Description
(i)抗原性呼吸器合胞体ウイルス(RSV)タンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第1組成物と、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第2組成物と
を含む組み合わせワクチンであって、組成物の1つは、プライム組成物であり、及び他の組成物は、ブースト組成物である、組み合わせワクチンに関する。
(i)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第1組成物と、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第2組成物と、
(iii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第3組成物と
を含む組み合わせワクチンであって、組成物の1つは、プライム組成物であり、及び他の組成物は、ブースト組成物である、組み合わせワクチンに関する。
(i)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第1組成物と、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第2組成物と、任意選択的に、
(iii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第3組成物と
を含むキットを含み得る。
(i)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第1組成物を対象に投与することと、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第2組成物を対象に投与することと、任意選択的に、
(iii)RSVウイルスの抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第3組成物を対象に投与することと
を含む方法に関する。
(i)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第1組成物を対象に投与することと、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第2組成物を対象に投与することと、任意選択的に、
(iii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量のアデノウイルスベクターを含む第3組成物を対象に投与することと
を含む。
18〜50歳の成人、RSV−血清陽性及びRSV−血清陰性の12〜24ヶ月の月齢の幼児におけるAd26.RSV.preFの安全性、耐容性及び免疫原性を評価するために、臨床研究をヒトにおいて実施する。
本発明の核酸分子によってコードされるRSV融合前Fタンパク質のアミノ酸配列
配列番号1:RSV preF2.2アミノ酸配列:
配列番号2:RSV preF2.1アミノ酸配列:
配列番号3:RSV F pre−F2.2融合前タンパク質をコードするコドン最適化核酸
配列番号4:RSV F pre−F2.1融合前タンパク質をコードするコドン最適化核酸
Claims (15)
- (i)抗原性呼吸器合胞体ウイルス(RSV)タンパク質をコードする核酸を含む免疫学的有効量の第1アデノウイルスベクターを含む第1組成物と、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量の第2アデノウイルスベクターを含む第2組成物と
を含む組み合わせワクチンであって、前記組成物の1つは、プライム組成物であり、及び他の組成物は、ブースト組成物である、組み合わせワクチン。 - (iii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量の第3アデノウイルスベクターを含む第3組成物
を更に含み、前記組成物の1つは、プライム組成物であり、及び他の組成物は、ブースト組成物である、請求項1に記載の組み合わせワクチン。 - 前記第1及び第2アデノウイルスベクターは、配列番号1又は2のアミノ酸配列を有するRSV Fタンパク質をコードする核酸を含む、請求項1又は2に記載の組み合わせワクチン。
- 前記第3アデノウイルスベクターは、配列番号1又は2のアミノ酸配列を有するRSV Fタンパク質をコードする核酸を含む、請求項2又は3に記載の組み合わせワクチン。
- 前記アデノウイルスベクターは、組換えAd26ベクターである、請求項1〜4のいずれか一項に記載の組み合わせワクチン。
- 対象においてRSVに対する免疫応答を誘導する方法であって、
(i)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量の第1アデノウイルスベクターを含む第1組成物を前記対象に投与することと、
(ii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量の第2アデノウイルスベクターを含む第2組成物を前記対象に投与することと
を含む方法。 - (iii)抗原性RSVタンパク質をコードする核酸を含む免疫学的有効量の第2アデノウイルスベクターを含む第3組成物を前記対象に投与すること
を更に含む、請求項6に記載の方法。 - 前記第1組成物(i)における前記アデノウイルスベクターは、配列番号1又は2のアミノ酸配列を有するRSVタンパク質をコードする核酸を含み、及び前記第2組成物(ii)における前記アデノウイルスベクターは、配列番号1又は2のアミノ酸配列を有するRSVタンパク質をコードする核酸を含み、任意選択的に、組成物(iii)における前記アデノウイルスベクターは、配列番号1又は2のアミノ酸配列を有するRSV Fタンパク質をコードする核酸を含む、請求項6又は7に記載の方法。
- 前記アデノウイルスベクターは、Ad26ベクターである、請求項6〜8のいずれか一項に記載の方法。
- 前記方法のステップ(i)及びステップ(ii)は、1〜12週間間隔、好ましくは2〜10週間、より好ましくは4〜8週間、より好ましくは4又は8週間間隔で実施される、請求項6〜9のいずれか一項に記載の方法。
- 前記方法のステップ(ii)及びステップ(iii)は、1〜12週間間隔、好ましくは2〜10週間、より好ましくは4〜8週間、より好ましくは4又は8週間間隔で実施される、請求項6〜10のいずれか一項に記載の方法。
- 前記対象は、約0〜24ヶ月の月齢、好ましくは約0〜12ヶ月の月齢、より好ましくは約0〜6ヶ月の月齢、より好ましくは2〜6ヶ月の月齢の小児である、請求項6〜11のいずれか一項に記載の方法。
- ステップ(i)は、約0〜2ヶ月の月齢の乳児で実施される、請求項6〜12のいずれか一項に記載の方法。
- 前記第1組成物は、約2ヶ月の月齢の乳児に投与され、及び前記第2組成物は、約3又は4ヶ月の月齢の前記乳児に投与される、請求項6〜13のいずれか一項に記載の方法。
- 前記第1組成物は、約2ヶ月の月齢の乳児に投与され、及び前記第2組成物は、約3又は4ヶ月の月齢の前記乳児に投与され、及び前記第3組成物は、約4又は6ヶ月の月齢の前記乳児に投与される、請求項6〜14のいずれか一項に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762507298P | 2017-05-17 | 2017-05-17 | |
US62/507,298 | 2017-05-17 | ||
EP17175629.9 | 2017-06-13 | ||
EP17175629 | 2017-06-13 | ||
PCT/EP2018/062604 WO2018210871A1 (en) | 2017-05-17 | 2018-05-15 | Methods and compositions for inducing protective immunity against rsv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020519663A true JP2020519663A (ja) | 2020-07-02 |
Family
ID=62530176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019563140A Pending JP2020519663A (ja) | 2017-05-17 | 2018-05-15 | Rsv感染に対する防御免疫を誘導するための方法及び組成物 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11229692B2 (ja) |
EP (1) | EP3624844A1 (ja) |
JP (1) | JP2020519663A (ja) |
AU (1) | AU2018267971A1 (ja) |
CA (1) | CA3061278A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
MX2018014699A (es) | 2016-05-30 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
AU2018267971A1 (en) * | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2019053109A1 (en) * | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011507533A (ja) * | 2007-12-24 | 2011-03-10 | アイディー バイオメディカル コーポレイション オブ ケベック | 組換えrsv抗原 |
JP2015512380A (ja) * | 2012-03-22 | 2015-04-27 | クルセル ホランド ベー ヴェー | Rsvに対するワクチン |
JP2016520039A (ja) * | 2013-04-25 | 2016-07-11 | クルセル ホランド ベー ヴェー | 安定化された可溶性融合前rsvfポリペプチド |
JP2016522230A (ja) * | 2013-06-17 | 2016-07-28 | クルセル ホランド ベー ヴェー | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) * | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
WO2017005848A1 (en) * | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
SI1445322T2 (sl) | 1995-06-15 | 2012-10-30 | Crucell Holland Bv | Pakirni sistemi za humani rekombinantni adenovirus za gensko terapijo |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
EP1760151B1 (en) | 1996-11-20 | 2012-03-21 | Crucell Holland B.V. | Adenovirus compositions obtainable by an improved production and purification method |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
DE69942708D1 (de) | 1998-02-17 | 2010-10-07 | Schering Corp | Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
CA2350890C (en) | 1998-11-16 | 2014-07-08 | Introgen Therapeutics, Inc. | Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
CA2372655C (en) | 1999-05-17 | 2011-11-15 | Crucell Holland B.V. | Recombinant adenovirus having low pre-existing neutralizing activity |
WO2003104467A1 (en) | 2002-04-25 | 2003-12-18 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
EP1263461A4 (en) | 2000-03-07 | 2009-08-12 | Merck & Co Inc | ADENOVIRUS FORMULATIONS |
EP1287159A4 (en) | 2000-05-08 | 2005-02-09 | Davisco Foods Int Inc | ENZYMATIC TREATMENT OF MOLECEPROTEINS FOR THE PRODUCTION OF BLOOD PRESSURE PENDING PEPTIDES, RESULTING PRODUCTS FROM THEREOF AND TREATMENT OF BLOOD PRESSURE IN MAMMALS |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
MXPA04006995A (es) | 2002-01-18 | 2005-07-13 | Schering Ag | Formulaciones estabilizadas de adenovirus. |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
KR101006594B1 (ko) | 2002-04-25 | 2011-01-07 | 크루셀 홀란드 비.브이. | 안정한 아데노바이러스 벡터 및 그 증식 방법 |
DK1506287T3 (da) | 2002-05-14 | 2007-08-20 | Merck & Co Inc | Fremgangsmåder til oprensning af adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
EP1585964A4 (en) | 2002-08-28 | 2008-07-16 | Introgen Therapeutics Inc | CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
EP1869171B2 (en) | 2005-04-11 | 2015-10-14 | Crucell Holland B.V. | Virus purification using ultrafiltration |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007110409A1 (en) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
US8772256B2 (en) | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
MX2011004292A (es) | 2008-11-03 | 2011-05-31 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales. |
WO2010086189A2 (en) | 2009-02-02 | 2010-08-05 | Okairòs Ag, Switzerland | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
MX2012000036A (es) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
WO2010149745A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
ES2563730T3 (es) | 2009-07-15 | 2016-03-16 | Glaxosmithkline Biologicals S.A. | Composiciones de proteína RSV F y procedimientos de fabricación de las mismas |
JP5762408B2 (ja) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法 |
DK2488636T3 (da) | 2009-10-15 | 2014-06-23 | Crucell Holland Bv | Fremgangsmåde til oprensning af adenoviruspartikler fra kulturer med høj celledensitet |
DK2488635T3 (en) | 2009-10-15 | 2014-02-24 | Crucell Holland Bv | A method for purifying adenovirus of cultures with high cell density |
US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
EP2536829B1 (en) | 2010-02-15 | 2016-04-06 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
CN103097412B (zh) | 2010-07-09 | 2016-08-10 | 克鲁塞尔荷兰公司 | 抗人呼吸道合胞病毒(rsv)抗体以及使用方法 |
HUE034673T2 (en) | 2011-05-13 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Pre-fusion Rsv F antigens |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
MX2015013065A (es) | 2013-03-13 | 2016-06-06 | Us Health | Proteinas f de rsv de prefusion y su uso. |
AU2014255864B2 (en) | 2013-04-15 | 2019-07-18 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
KR102201555B1 (ko) | 2013-04-15 | 2021-01-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv g 단백질에 결합하는 인간 항체 |
JP6685903B2 (ja) | 2013-07-25 | 2020-04-22 | アバター・メディカル・エルエルシー | 立体構造的に安定化されたrsv融合前fタンパク質 |
ES2711115T3 (es) | 2013-09-19 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Formulaciones de adenovirus mejoradas |
AU2017248018A1 (en) * | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
AU2018267971A1 (en) * | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
WO2019053109A1 (en) * | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
-
2018
- 2018-05-15 AU AU2018267971A patent/AU2018267971A1/en active Pending
- 2018-05-15 CA CA3061278A patent/CA3061278A1/en active Pending
- 2018-05-15 EP EP18729330.3A patent/EP3624844A1/en not_active Withdrawn
- 2018-05-15 JP JP2019563140A patent/JP2020519663A/ja active Pending
- 2018-05-15 US US16/613,206 patent/US11229692B2/en active Active
-
2022
- 2022-01-18 US US17/577,704 patent/US20220125910A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011507533A (ja) * | 2007-12-24 | 2011-03-10 | アイディー バイオメディカル コーポレイション オブ ケベック | 組換えrsv抗原 |
JP2015512380A (ja) * | 2012-03-22 | 2015-04-27 | クルセル ホランド ベー ヴェー | Rsvに対するワクチン |
JP2016520039A (ja) * | 2013-04-25 | 2016-07-11 | クルセル ホランド ベー ヴェー | 安定化された可溶性融合前rsvfポリペプチド |
JP2016522230A (ja) * | 2013-06-17 | 2016-07-28 | クルセル ホランド ベー ヴェー | 安定化された可溶性融合前rsv fポリペプチド |
WO2017005844A1 (en) * | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
WO2017005848A1 (en) * | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
Non-Patent Citations (1)
Title |
---|
WIDJOJOATMODJO, M. N. ET AL.: "Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial", VACCINE, vol. 33, no. 41, JPN6022017648, 2015, pages 5406 - 5414, XP029277470, ISSN: 0004942645, DOI: 10.1016/j.vaccine.2015.08.056 * |
Also Published As
Publication number | Publication date |
---|---|
US20220125910A1 (en) | 2022-04-28 |
EP3624844A1 (en) | 2020-03-25 |
US20200061181A1 (en) | 2020-02-27 |
US11229692B2 (en) | 2022-01-25 |
AU2018267971A1 (en) | 2019-11-07 |
CA3061278A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7366014B2 (ja) | アデノウイルス及びその用途 | |
JP7229239B2 (ja) | アデノウイルスベクター及びその用途 | |
JP7285833B2 (ja) | アデノウイルス及びその用途 | |
JP6230527B2 (ja) | サルアデノウイルス及び雑種アデノウイルスベクター | |
AU2013237429B2 (en) | Vaccine against RSV | |
US20220125910A1 (en) | Methods and compositions for inducing protective immunity against rsv infection | |
WO2020063370A2 (zh) | 免疫组合物及其制备方法与应用 | |
US9125870B2 (en) | Vaccine against RSV | |
IL272281B2 (en) | Methods and preparations for heterologous reprna vaccines | |
JP7438943B2 (ja) | アデノウイルス及びその用途 | |
US11859199B2 (en) | Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof | |
WO2019021305A1 (en) | VACCINE AGAINST FOOT AND MOUTH DISEASE | |
CN111479926A (zh) | 具有两个表达盒的猿猴腺病毒载体 | |
WO2018210871A1 (en) | Methods and compositions for inducing protective immunity against rsv infection | |
US20220372515A1 (en) | Adenovirus vectors and uses thereof | |
JP7240390B2 (ja) | 増強されたプロモーター | |
EA044526B1 (ru) | Аденовирус и пути его применения | |
EA042952B1 (ru) | Аденовирус и пути его применения | |
EA044813B1 (ru) | Аденовирус и его применения | |
EA039001B1 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
IL234758A (en) | Rsv vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210512 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221213 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230606 |